Skip to main content
. Author manuscript; available in PMC: 2007 Oct 26.
Published in final edited form as: Prostate. 2002 Nov 1;53(3):183–191. doi: 10.1002/pros.10136

Fig. 3.

Fig. 3.

Recombinant vaccinia encoding a model TAA (β-gal) induces TAA-specific immunity in vivo against RM-1 prostate cancer cells. C57BL/6 mice were immunized with 107 plaque forming units/mouse of rVV-β-gal (filled symbols) or control vector V69 (open symbols).Three weeks later, immunized mice were challenged with 105 D7RM-1 tumor cells subcutaneously and followed up for tumor-related death (n=10 mice per therapy group; P=0.002). Similar findings confirmed in three separate experiments.